000907382 001__ 907382
000907382 005__ 20250106101717.0
000907382 0247_ $$2doi$$a10.3389/fnume.2022.850414
000907382 0247_ $$2Handle$$a2128/31086
000907382 0247_ $$2altmetric$$aaltmetric:126595386
000907382 0247_ $$2pmid$$a39354976
000907382 0247_ $$2WOS$$aWOS:001376880800001
000907382 037__ $$aFZJ-2022-02003
000907382 082__ $$a610
000907382 1001_ $$0P:(DE-HGF)0$$aZippel, Claus$$b0
000907382 245__ $$aCyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends
000907382 260__ $$aLausanne$$bFrontiers Media$$c2022
000907382 3367_ $$2DRIVER$$aarticle
000907382 3367_ $$2DataCite$$aOutput Types/Journal article
000907382 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1651144883_20692
000907382 3367_ $$2BibTeX$$aARTICLE
000907382 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000907382 3367_ $$00$$2EndNote$$aJournal Article
000907382 520__ $$aBackground: Cyclotrons form a central infrastructure and are a resource of medical radionuclides for the development of new radiotracers as well as the production and supply of clinically established radiopharmaceuticals for patient care in nuclear medicine.Aim: To provide an updated overview of the number and characteristics of cyclotrons that are currently in use within radiopharmaceutical sciences and for the development of radiopharmaceuticals to be used for patient care in Nuclear Medicine in Germany (D), Austria (A) and Switzerland (CH).Methods: Publicly available information on the cyclotron infrastructure was (i) consolidated and updated, (ii) supplemented by selective desktop research and, last but not least, (iii) validated by members of the committee of the academic “Working Group Radiochemistry and Radiopharmacy” (AGRR), consisting of radiochemists and radiopharmacists of the D-A-CH countries and belonging to the German Society of Nuclear Medicine (DGN), as well as the Radiopharmaceuticals Committee of the DGN.Results: In total, 42 cyclotrons were identified that are currently being operated for medical radionuclide production for imaging and therapy in Nuclear Medicine clinics, 32 of them in Germany, 4 in Austria and 6 in Switzerland. Two thirds of the cyclotrons reported (67%) are operated by universities, university hospitals or research institutions close to a university hospital, less by/in cooperation with industrial partners (29%) or a non-academic clinic/ PET-center (5%). Most of the cyclotrons (88%) are running with up to 18 MeV proton beams, which is sufficient for the production of the currently most common cyclotron-based radionuclides for PET imaging.Discussion: The data presented provide an academically-updated overview of the medical cyclotrons operated for the production of radiopharmaceuticals and their use in Nuclear Medicine in the D-A-CH countries. In this context, we discuss current developments and trends with a view to the cyclotron infrastructure in these countries, with a specific focus on organizational aspects.
000907382 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000907382 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000907382 7001_ $$0P:(DE-Juel1)131818$$aErmert, Johannes$$b1
000907382 7001_ $$0P:(DE-HGF)0$$aPatt, Marianne$$b2
000907382 7001_ $$0P:(DE-HGF)0$$aGildehaus, Franz Josef$$b3
000907382 7001_ $$0P:(DE-HGF)0$$aRoss, Tobias L.$$b4
000907382 7001_ $$0P:(DE-HGF)0$$aReischl, Gerald$$b5
000907382 7001_ $$0P:(DE-HGF)0$$aKuwert, Torsten$$b6
000907382 7001_ $$0P:(DE-HGF)0$$aSolbach, Christoph$$b7
000907382 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b8
000907382 7001_ $$0P:(DE-HGF)0$$aKiss, Oliver$$b9
000907382 7001_ $$0P:(DE-HGF)0$$aMitterhauser, Markus$$b10
000907382 7001_ $$0P:(DE-HGF)0$$aWadsak, Wolfgang$$b11
000907382 7001_ $$0P:(DE-HGF)0$$aSchibli, Roger$$b12
000907382 7001_ $$0P:(DE-HGF)0$$aKopka, Klaus$$b13$$eCorresponding author
000907382 773__ $$0PERI:(DE-600)3110523-3$$a10.3389/fnume.2022.850414$$gVol. 2, p. 850414$$p850414$$tFrontiers in nuclear medicine$$v2$$y2022
000907382 8564_ $$uhttps://juser.fz-juelich.de/record/907382/files/fnume-02-850414.pdf$$yOpenAccess
000907382 909CO $$ooai:juser.fz-juelich.de:907382$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000907382 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131818$$aForschungszentrum Jülich$$b1$$kFZJ
000907382 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b8$$kFZJ
000907382 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000907382 9141_ $$y2022
000907382 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000907382 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000907382 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000907382 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-03-07T15:54:27Z
000907382 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-03-07T15:54:27Z
000907382 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-03-07T15:54:27Z
000907382 920__ $$lyes
000907382 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000907382 980__ $$ajournal
000907382 980__ $$aVDB
000907382 980__ $$aUNRESTRICTED
000907382 980__ $$aI:(DE-Juel1)INM-5-20090406
000907382 9801_ $$aFullTexts